Danimer Scientific (DNMR) Misses Q3 EPS by 13c, offers outlook

Danimer Scientific (NYSE: DNMR) reported Q3 EPS of ($0.39), $0.13 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $14.74 million.

Outlook

The Company’s previous full-year adjusted EBITDA guidance range was based on expected strong second half revenue growth through new customer product launches and associated first shipments that did not materialize as planned. Accordingly, the Company has modified its full-year 2023 adjusted EBITDA guidance to a range of $(40) million to $(37) million and will look forward to finalizing a number of expected product launches in 2024. Separately, the Company now anticipates full-year capital expenditures in the range of $27 million to $29 million, which is a revision toward the more favorable end of its wider previous range.

For earnings history and earnings-related data on Danimer Scientific (DNMR) click here.

You May Also Be Interested In

• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c